|Bid||0.000 x 1100|
|Ask||0.000 x 3200|
|Day's Range||0.940 - 0.977|
|52 Week Range||0.810 - 12.800|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.75|
Additionally, Pain Therapeutics issued unregistered warrants to purchase up to 8,860,778 shares of its common stock, at a purchase price of $0.125 per warrant, for gross proceeds of approximately $1.11 million. The warrants have an exercise price of $1.25 per share of common stock, are exercisable immediately and will expire two and one-half years from the issuance date. The net proceeds of the offering are estimated to be approximately $10.3 million, after deducting placement agent fees and other estimated offering expenses. The shares of common stock (but not the warrants or the shares of common stock underlying the warrants) were offered by Pain Therapeutics pursuant to a "shelf" registration statement on Form S-3 that was originally filed on April 14, 2017 and declared effective by the Securities and Exchange Commission ("SEC") on July 31, 2017 and the base prospectus contained therein (File No. 333-217319).
Nearly two weeks after the FDA rejected its lead drug candidate, Pain Therapeutics is putting together a rebound effort aimed at an entirely new ailment.
Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.
NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natural ...
Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.
NEW YORK, NY / ACCESSWIRE / August 16, 2018 / Shares of Tesla dropped on Wednesday as traders learned that the company has been hit with a subpoena by the SEC regarding CEO Elon Musk's tweet about considering to take the company private and having funding secured. Shares of Pain Therapeutics were skyrocketing on news that the company has received an Alzheimer's grant. Pain Therapeutics, Inc. shares closed up nearly 77% yesterday on about 18.8 million shares traded.
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional investors for the purchase of 8,860,778 shares of its common stock, at a purchase price per share of $1.15, for gross proceeds of approximately $10.19 million, in a registered direct offering priced at-the-market. Additionally, Pain Therapeutics has also agreed to issue to the investors unregistered warrants to purchase up to 8,860,778 shares of common stock, at a purchase price per warrant of $0.125, for gross proceeds of approximately $1.11 million. The warrants have an exercise price of $1.25 per share of common stock, will be exercisable immediately and will expire two and one-half years from the issuance date.
Pain Therapeutics notes that the grant is for a total of $3.20 million. PTI-125 is a new drug that Pain Therapeutics is developing to treat Alzheimer’s disease. The drug is a molecule that has the potential to treat Alzheimer’s disease.
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced that the National Institutes of Health (NIH) has awarded the Company a $3.2 million clinical research grant to support a Phase II study with PTI-125, the Company’s drug candidate to treat Alzheimer’s disease. Pain Therapeutics expects to initiate the study in Q4 2018.
It's "a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," the drugmaker's CEO said as he announced a major pivot away from painkillers to Alzheimer's.
The FDA rejected Pain’s lead asset and said the drug’s negatives outweigh its positives. "This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," Pain Therapeutics CEO Remi Barbier said in a statement. Pain Therapeutics said it will redirect its resources to advance its Alzheimer’s assets.
CUPERTINO, Calif. , Aug. 6, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) reported that it received a Complete Response Letter ...
Pain Therapeutics Inc. shares (ptie) slid 21% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has rejected its non-opioid pain treatment, Remoxy. The company said it has received a Complete Response Letter from the FDA, saying the data submitted in its new drug application "do not support the conclusion that the benefits of [REMOXY] Extended-Release Capsules outweigh the risks." Pain Therapeutics Chief Executive Remi Barbier said it was a "bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction.
Pain Therapeutics said on Monday that the U.S. Food and Drug Administration declined to approve its opioid drug for the management of severe pain as the benefits of the drug did not outweigh the risk. "This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," said Chief Executive Officer Remi Barbier said in a statement. The FDA's "complete response letter" marks the latest setback to the U.S. drug developer and the treatment, Remoxy ER, which has failed to get marketing approval on the past three attempts.
Pain Therapeutics, Inc. (PTIE) today announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY, an abuse-deterrent, extended-release form of oxycodone. The Company believes its program in Alzheimer’s disease has game-changing characteristics. PTI-125, the lead drug candidate, is a small molecule that has a unique mechanism of action for treating Alzheimer’s disease. The underlying science for PTI-125 is published in prestigious technical journals, including Journal of Neuroscience, Neurobiology of Aging, and Neuroimmunology and Neuroinflammation, with additional publications pending. PTI-125 recently completed a successful Phase I clinical-stage program, funded by a peer-reviewed research grant from the National Institutes of Health (NIH).
Earnings is providing a much-needed boost to the biotech sector last week, with big-name companies like Eli Lilly And Co (NYSE: LLY ) and Pfizer Inc. (NYSE: PFE ) all trading at fresh 52-week highs in ...
Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is up about 5 percent. As the earnings season kicks ...
AUSTIN, Texas, July 26, 2018-- Pain Therapeutics, Inc., a drug development company, today reported financial results for the second quarter ended June 30, 2018. Net loss was $2.5 million, or $0.36 per ...
This week was a rough one for biotech company Pain Therapeutics, Inc. (NASDAQ:PTIE) after the firm’s pain drug, Remoxy ER, was shot down by the FDA advisory committee. PTIE stock had been trading at more than $9 per share ahead of the news and investors were hopeful about the drug’s potential. The biotech space is a risky one because FDA approval weighs so heavily on companies’ success.
Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 26) AngioDynamics, Inc. (NASDAQ: ANGO ) Chembio Diagnostics Inc ...
CUPERTINO, Calif. , June 26, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today reported that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety ...
AUSTIN, Texas, June 26, 2018-- Pain Therapeutics, Inc., a drug development company, today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety ...